


Accepted Manuscript

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving

Jagpreet Chhatwal, PhD, Tianhua He, Chin Hur, MD, MPH, Maria A. Lopez-Olivo, MD, PhD



PII: S1542-3565(16)30673-5
DOI: [10.1016/j.cgh.2016.09.015](https://doi.org/10.1016/j.cgh.2016.09.015)
Reference: YJCGH 54917

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 6 September 2016

Please cite this article as: Chhatwal J, He T, Hur C, Lopez-Olivo MA, Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving, *Clinical Gastroenterology and Hepatology* (2016), doi: 10.1016/j.cgh.2016.09.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving

Jagpreet Chhatwal, PhD^{1,2,3} Tianhua He,⁴ Chin Hur, MD, MPH^{1,2,3} Maria A. Lopez-Olivo, MD, PhD⁵

¹Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA

²Harvard Medical School, Boston, MA, USA

³Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA

⁴Tsinghua University School of Medicine, Beijing, China.

⁵Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abbreviations: HCV, hepatitis C virus; DAA, direct-acting antiviral; CEA, cost-effectiveness analysis; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; DARE, Database of Abstracts of Reviews of Effects; NHS EED, National Health Service Economic Evaluation Database; CHEERS, The Consolidated Health Economic Evaluation Reporting Standards; WTP, willingness to pay.

Word count: 3,976

Number of figures and tables: 6

Correspondence: Jagpreet Chhatwal, PhD
MGH Institute for Technology Assessment
101 Merrimac Street, Floor 10th
Boston, MA 02114
Email: jagchhatwal@mgh.harvard.edu
Phone: 1-617-724-4445
Fax: 1-617-726-9414

Grant support: This project was funded by Gilead Sciences, Inc. Funding source had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Disclosures: Chhatwal has received a research grant from Gilead Sciences, and consulting fee from Gilead Sciences, Merck & Co. Inc. Other authors have no conflict of interest.

Authors contributions: study concept and design: Chhatwal, He, Hur, Angeles-Lopez, experiments and procedures: Chhatwal and He; writing of article: Chhatwal, Angeles-Lopez

Download English Version:

<https://daneshyari.com/en/article/5657556>

Download Persian Version:

<https://daneshyari.com/article/5657556>

[Daneshyari.com](https://daneshyari.com)